STUDY OBJECTIVE: To describe the characteristics and clinical outcomes of hematopoietic stem cell transplant (HSCT) recipients who received adjunctive cytomegalovirus intravenous immune globulin (CMV-IVIG) for probable or proven CMV disease. DESIGN: Retrospective cohort study. SETTING: Large, university-affiliated, tertiary-care medical center. PATIENTS: Thirty-five adult HSCT recipients who received at least one dose of CMV-IVIG for adjunctive treatment of probable or proven CMV disease between January 1, 1999, and December 31, 2007. MEASUREMENTS AND MAIN RESULTS: All-cause mortality at hospital discharge was the primary outcome. All patients received an allogeneic HSCT. Twenty-six patients (74%) had pneumonitis, nine (26%) had enteritis, and 29 (83%) had CMV viremia. All patients received concomitant antiviral therapy; 31 (89%) received ganciclovir, and 14 (40%) received foscarnet. All-cause mortality at hospital discharge was 49% (17 patients). Patient characteristics associated with mortality included requiring intubation for CMV pneumonia (11 [79%] of 14 nonsurvivors vs 3 (25%) of 12 survivors, p=0.016) and earlier disease onset after HSCT (median 48 days for nonsurvivors vs 106 days for survivors, p<0.001). In the multivariate analysis, only requiring intubation for CMV pneumonia remained a significant risk factor for increased mortality. A low rate of adverse events was attributed to CMV-IVIG, with mild hypertension (two patients [6%]) and erythema and chills (one patient [3%]) being the most common. CONCLUSION: The mortality rate in our study population was similar to previous reports in the literature and may be somewhat lower than rates reported with antiviral monotherapy. Our analysis suggests that factors associated with mortality include the need for intubation and, possibly, earlier onset of CMV disease after HSCT. Treatment with CMV-IVIG appears to be well tolerated in HSCT recipients. These findings support further trials of CMV-IVIG efficacy in this setting.
STUDY OBJECTIVE: To describe the characteristics and clinical outcomes of hematopoietic stem cell transplant (HSCT) recipients who received adjunctive cytomegalovirus intravenous immune globulin (CMV-IVIG) for probable or proven CMV disease. DESIGN: Retrospective cohort study. SETTING: Large, university-affiliated, tertiary-care medical center. PATIENTS: Thirty-five adult HSCT recipients who received at least one dose of CMV-IVIG for adjunctive treatment of probable or proven CMV disease between January 1, 1999, and December 31, 2007. MEASUREMENTS AND MAIN RESULTS: All-cause mortality at hospital discharge was the primary outcome. All patients received an allogeneic HSCT. Twenty-six patients (74%) had pneumonitis, nine (26%) had enteritis, and 29 (83%) had CMV viremia. All patients received concomitant antiviral therapy; 31 (89%) received ganciclovir, and 14 (40%) received foscarnet. All-cause mortality at hospital discharge was 49% (17 patients). Patient characteristics associated with mortality included requiring intubation for CMV pneumonia (11 [79%] of 14 nonsurvivors vs 3 (25%) of 12 survivors, p=0.016) and earlier disease onset after HSCT (median 48 days for nonsurvivors vs 106 days for survivors, p<0.001). In the multivariate analysis, only requiring intubation for CMV pneumonia remained a significant risk factor for increased mortality. A low rate of adverse events was attributed to CMV-IVIG, with mild hypertension (two patients [6%]) and erythema and chills (one patient [3%]) being the most common. CONCLUSION: The mortality rate in our study population was similar to previous reports in the literature and may be somewhat lower than rates reported with antiviral monotherapy. Our analysis suggests that factors associated with mortality include the need for intubation and, possibly, earlier onset of CMV disease after HSCT. Treatment with CMV-IVIG appears to be well tolerated in HSCT recipients. These findings support further trials of CMV-IVIG efficacy in this setting.
Authors: Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang Journal: Crit Care Med Date: 2006-06 Impact factor: 7.598
Authors: A Asberg; A Humar; H Rollag; A G Jardine; H Mouas; M D Pescovitz; D Sgarabotto; M Tuncer; I L Noronha; A Hartmann Journal: Am J Transplant Date: 2007-07-19 Impact factor: 8.086
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: N G Almyroudis; A Jakubowski; D Jaffe; K Sepkowitz; E Pamer; R J O'Reilly; G A Papanicolaou Journal: Transpl Infect Dis Date: 2007-05-19 Impact factor: 2.228
Authors: E Ozdemir; R M Saliba; R E Champlin; D R Couriel; S A Giralt; M de Lima; I F Khouri; C Hosing; S M Kornblau; P Anderlini; E J Shpall; M H Qazilbash; J J Molldrem; R F Chemaly; K V Komanduri Journal: Bone Marrow Transplant Date: 2007-05-28 Impact factor: 5.483
Authors: O H Negm; B MacKenzie; M R Hamed; O A J Ahmad; C C Shone; D P Humphreys; K Ravi Acharya; C E Loscher; I Marszalowska; M Lynch; M H Wilcox; T M Monaghan Journal: Clin Exp Immunol Date: 2017-03-16 Impact factor: 4.330
Authors: Michael Boeckh; Terry Stevens-Ayers; Giovanna Travi; Meei-Li Huang; Guang-Shing Cheng; Hu Xie; Wendy Leisenring; Veronique Erard; Sachiko Seo; Louise Kimball; Lawrence Corey; Steven A Pergam; Keith R Jerome Journal: J Infect Dis Date: 2017-05-15 Impact factor: 7.759
Authors: Michael P Weekes; Peter Tomasec; Edward L Huttlin; Ceri A Fielding; David Nusinow; Richard J Stanton; Eddie C Y Wang; Rebecca Aicheler; Isa Murrell; Gavin W G Wilkinson; Paul J Lehner; Steven P Gygi Journal: Cell Date: 2014-06-05 Impact factor: 41.582
Authors: Alimuddin Zumla; Martin Rao; Robert S Wallis; Stefan H E Kaufmann; Roxana Rustomjee; Peter Mwaba; Cris Vilaplana; Dorothy Yeboah-Manu; Jeremiah Chakaya; Giuseppe Ippolito; Esam Azhar; Michael Hoelscher; Markus Maeurer Journal: Lancet Infect Dis Date: 2016-04 Impact factor: 25.071